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IL-2 given either aloneor incombination withthe administration oflymphokine-
activated killer (LAK)' cells has been shown to mediate the regression ofestablished
metastatic tumor both in mice and man (1-3). Furthermore, adoptive transfer of
tumor-infiltrating lymphocytes (TIL) concomitant with the administration ofIL-2
canmediate antitumoreffectsthatare 50-100 times more potent in murine metastatic
tumormodels thanthose observed withLAK cells(4, 5). In earlyhuman trials using
TIL, regression ofestablished metastatic disease has been observed in selected pa-
tients (6, 7).
In 6- and 14-d murine metastatic models, however, successful TIL therapy is de-
pendenton theuseofeither cyclophosphamide (CP) orwholebodyirradiation(WBX)
(4). The reason forthis requirement remainsunclear, but reports have demonstrated
that mice bearingimmunogenic tumors develop suppressor cellscapableofinhibiting
the antitumor activity ofadoptively transferred Lyt-2+ cytotoxic lymphocytes (8, 9).
To assess thepossible role ofimmunosuppression, suppressor cells, and direct an-
titumoractivity ofCP andWBXin theaugmentation ofthe antitumoractivity medi-
ated by Lyt-2+ TIL and IL-2, we first compared WBX with local tumor radiation
(LTX) in the treatment ofestablished 7-d liver metastases. We also assessed the re-
quirement for CP in B mice that were devoid ofmature T cells and, therefore, any
Ts cell activity. When taken together, our results strongly suggest that the effects
of CP and WBX that combine with Lyt-2+ TIL to mediate antitumor activity
against established 7-d hepaticmetastases do notinvolveimmunosuppression orthe
elimination of suppressor cells, but rather a direct antitumor activity.
Materials and Methods
Mice.
￿
Female C57BL/6 mice were used in all experiments. Mice were 8 wk of age when
undergoing thymectomy. All othermice were at least 12 wk of agewhen used in experiments,
and were obtained from the Small Animal Section, Veterinary Resources Branch, Division
of Research Services, National Institutes of Health, Bethesda, MD.
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Tumors.
￿
MC-38 is a weakly immunogenic murine adenocarcinoma induced by the sub-
cutaneous injection of dimethylhydrazine and passaged subcutaneously in mice. Single cell
suspensions were prepared as previously described (2). Briefly, growing subcutaneous tumors
were harvested and digested with a triple enzyme solution containing 0.1% collagenase, type
IV; 0.01% hyaluronidase, type V; and 0.002 % DNase, type I (Sigma Chemical Co., St. Louis,
MO). The resulting single cell suspensions were washed in HBSS (Biofluids, Rockville, MD),
counted, and diluted to a concentration of 5 x 105 cells/ml for induction of experimental
liver metastases.
Medium.
￿
In vitro culture ofTIL was performed incomplete medium consisting ofRPMI
1640 medium (Biofluids) supplemented with 10% heat-inactivated FCS (Biofluids), 0.03%
fresh glutamine (NIH Media Unit), 0.1 mM nonessential amino acids (M . A. Bioproducts,
Walkersville, MD), 1 mM sodium pyruvate (Biofluids), 5 x 10-5 M 2-ME (Aldrich Chem-
ical Co., Milwaukee, WI), 100 U/ml penicillin (NIH Media Unit), 100 kg/ml streptomycin
(NIH Media Unit), 50 ug/ml gentamicin (Schering, Kenilworth, NJ), and 0.5 p,g/ml am-
photericin B (Flow Laboratories, McLean, VA).
Lymphokines.
￿
Human rIL-2 was kindly supplied by Cetus Corp., Emeryville, CA. The
sp act was 3.0 x 106 Cetus U/mg (8 x 106 Biological Response Modifiers Program U/N.g),
and the endotoxin level was <0.024 ng/ml, as measured by limulus amoebocyte lysate assay.
TIL.
￿
Thy-1.2`, Lyt-2.
, tumor-specific cytotoxic TIL were grown from subtaneous MC-
38 tumors using a method described previously (5). In some experiments, however, a method
slightly modified from that described earlier was used. Briefly, in these experiments, subcuta-
neous tumors were digested with triple enzymes as descrbed above. Thy-1.2' lymphocytes
were isolated from the resulting single cell suspensions by incubating 108 tumor cells/ml with
108 Dynabeads M-450 immunomagnetic beads/ml (Dynal Inc., Great Neck, NY) previously
coated with antiThy-1.2 antibody (New England Nuclear, Boston, MA) for 45 min at 4°C.
The lymphocyte/bead complexes were then extracted with a magnet and cultured at 37'C
in complete medium (CM) containing 10 U/ml ofIL-2 . After 24 h, lymphocytes that had fallen
offthe beads were harvested and placed into culture at 105 cells/ml in CM containing 10 U/ml
of IL-2. Initially, 5 x 105 splenocytes/ml irradiated with 3,000 cGy were added as feeders,
and 105 tumor cells/ml irradiated with 10,000-30,000 cGy were added as specific stimulator
cells. Subsequently, growing lymphocytes were diluted to a concentration of 105 cells/ml and
supplemented every 7-10 d with 2-4 x 105 splenocytes/ml and 1-2 x 105 tumor cells/ml.
Both splenocytes and tumor cells were irradiated with 3,000 cGy before addition to TIL cul-
tures. These TIL, when free of tumor cells, were used in therapy experiments, and were
identical in both phenotype and specificity to those derived from the previously described
method (10).
Local Irradiation.
￿
Mice treated with local liver irradiation were first anesthetized with
0.2-0.225 ml of a 7% pentobarbital solution (Somnifer; Richmond Veterinary Supply Co.,
Richmond, VA) and placed into a lead holder. Appropriate lead shields were used to cover
nothing (WBX), the liver, the entire body except the liver, or in some experiments, the entire
body except one-halfof the liver. Mice were then irradiated with an X-ray machine (RT 250;
Philips Electronic Instruments, Inc., Mahwah, NJ) operating at 235 kV and 15 mamps (0.25-
mm Cu and 0.55-mm Al filtration) delivering 63 cGy/min. After irradiation, animals within
each treatment group were allowed to recover from anesthesia, randomized, and distributed
to cages.
B Mice.
￿
B mice were generated using 8-wk-old C57BL/6 mice as previously described
(11). Briefly, mice were anesthetized with 0.25 ml ofa 7 % pentobarbital solution, and a thymec-
tomy was performed. Mice were then allowed to recover for a period of 2 wk. Subsequently,
the mice were lethally irradiated using a 137CS irradiator (Gammacell 40) delivering 109
cGy/min (Atomic Energy ofCanada Ltd., Kanata, Ontario, Canada), and immediately recon-
stituted with 5 x 106 T-depleted bone marrow cells. Normal C57BL/6 bone marrow cells
were depleted ofT lymphocytes by incubating 108 bone marrow cells/ml in rabbit anti-mouse
brain antibody (kindly provided by Dr. David Sachs, Immunology Branch, NCI, Bethesda,
MD) diluted 1 :50 in Ca2'-, Mgt'-free HBSS (Biofluids) for 45 min at 4'C, followed by 30
min ofincubation with guinea pigcomplement (Gibco Laboratories, Grand Island, NY) diluted
1 :3 in Ca2t, Mgt'-free HBSS. Mice were then allowed to recover for an additional 2 wk
before use in therapy experiments.CAMERON ET AL.
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Mixed Lymphocyte Response Assay.
￿
Splenocytes harvested from B mice were assayed for re-
sponsiveness to allogeneic antigens as a measure of T cell function. Spleens from three ran-
domly selected B mice were sterilelyharvested and crushed. The splenocytes were then filtered
through 112-,m nylon mesh (Nitex; Lawshe Industrial Co., Bethesda, MD) . The resulting
single cell suspensionwas washed three times after lysing the RBC with ACK lysing buffer
(NIH Media Unit). After resuspending the cells in complete media, 105 cells in 0.1 ml were
plated into 96-well flat-bottomed plates. Three spleens were harvested in an identical fashion
from normal animals, and a single cell suspension of normal splenocytes was prepared as
a positive control. Stimulator cells were prepared from normal C57BL/6 and DBA spleno-
cytes and irradiated to 3,000 cGy. After resuspension in complete media, 105 ofthese spleno-
cytes in 0.1 ml were plated into triplicate wells containing the responding cells, as well as
three control wellscontaining media alone. CM was added to three wellscontaining responding
cells as additional controls. The plates were then incubated at 37°C and 5% COZ for 2 or
4 d. On day 2 or 4, 1 mci of [3H]thymidine (New England Nuclear, Boston, MA) was added
to each well. After 6 h of additional incubation, the cells were harvested on a PHD cell har-
vester (Cambridge Technology, Inc., Cambridge, MA), 3 ml of scintillation fluid was added,
and the radioactivity was measured on a S liquid scintillation counter (LKB Instruments,
Inc., Gaithersburg, MD). The uptake of [3H]thymidine in cpm was then used as a measure
of stimulation.
Generation ofLiver Metastases.
￿
Multiple liver metastases.were induced by the intrasplenic
injection of single cell tumor preparations, as previously described (12). Briefly, C57BL/6
mice were anesthesized with 0.2-0.225 ml of a 7 % Somnifer solution and then immobilized.
A left subcostal incision (5-7 mm) was then made and the spleen externalized and isolated
with a sterile 2 x 2-inch gauze. A 25-gauge needle (American Hospital Supply, Chicago,
IL) was used to puncture the splenic capsule and inject 5 x 105 tumor cells in 1.0 ml directly
into the spleen. Gentle pressure was applied for a period of 1 min to prevent hemorrhage
and tumor cell extravasation. The splenic pedicle was then clamped with a medium hemoclip
(Edward Weck & Company, Inc., Research Triangle Park, NC) and the spleen removed. The
skin and abdominal wall were closed in one layer with 9-mm Autoclip wound clips (Clay
Adams, Parsippany, NJ). The mice were allowed to recover and themwere randomized before
beingdistributed to isolator cages. At the conclusion (day.16 or 17) of experiments designed
to determine the number oflivermetastases, mice were randomized and ear tagged. 0.75-1.0
ml of a 15 % India ink solution was then injected via the lateral tail vein, after which 0.1
ml of 100% pentobarbital was injected intraperitoneally to kill the mice. The stained livers
were collected and placed into Fekete's solution for at least1 h to bleach the metastases, which
stand out as white nodules against a black background, of normal liver parenchyma. The
livers were divided into right-sided lobes (three) and left-sided lobes (four) of approximately
equal volume. The tumor nodules were then blindly counted and recorded.
ClonogenicAssay.
￿
Single cell suspensions were prepared by triple enzyme digestion, as de-
scribed above, from livers bearing MC-38 metastases: The cellswere washed three times and
resuspended in CM. Triplicate samples were plated into six-well plates from each offive serial
1 :10 dilutions prepared from a suspension containing 10' cells/ml. The cells were thoroughly
mixed in the wells and allowed to incubate for 14
￿
at 37°C in 5% CO2. After 2 wk, the
adherent cells were fixed with 25% methanol and stained with 5% crystal violet in a 10%
ethanol solution (NIH Media Unit). The number of colonies was then blindly counted and
the number of colonies per 106 original cells determined.
Immunotherapy Model.
￿
Multiple livermetastases were induced on day 0 as described above.
After 6 d, when metastatic nodules could be identified on the surface of the liver, mice were
treated with LTX, WBX, or WBX with liver shielding. On day 7, some mice were given
a single injection of TIL intravenously, and then IL.-2-was administered intraperitoneally
thrice daily for 5 d. After treatment, mice were followed for survival or killed on day 17 for
enumeration of liver metastases. In survival experiments, all dead animals were autopsied
for evidence of tumor.
Statistical Analysis.
￿
In experiments enumerating the number of livermetastases, compar-
isons were made using the Kaplan-Meier method and Mantel-Haenszel test for significance
within groups. Survival analyses were performed using the Kruskal-Wallis test . All p values
are two tailed.252
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Results
The Effect of LTX on Immunotherapy with TIL and IL-2.
￿
To assess the impact of
LTX on the effectiveness ofimmunotherapy with TIL and IL-2, LTX was directly
compared with our previouslypublished regimen usingWBX (4). Micebearingmul-
tiple 6-d hepatic metastases were treatedwith 750-cGy X-ray irradiation tothewhole
body, to theliveralone, or tothe whole body, shielding the liver. An additionalgroup
ofmice received no radiation therapy. All mice receiving 750-cGy WBX were im-
mediately reconstituted with 1-1.3 x 107 normal bone marrow cells. 1 d after irra-
diation, groups of six mice from each radiation group were randomly placed into
oneofthree treatment regimens: HBSS (0.5 ml i.p.) thrice daily for5 d, IL-2 (50,000
U i.p.) thrice daily for 5 d, or 1-2.0 x 107 TIL intravenously on day 7 followed by
IL-2 (50,00 U i.p.) thrice daily for 5 d. After completion oftherapy, the mice were
followed for survival. Fig. 1 represents data compiled from four identical experi-
ments. As shown in the top frame, there was no efficacy to treatment with TIL and
IL-2 ifnoradiation was given(median survival times [MST] = 11.5, 17.0, and 15.( d
with HBSS, IL-2, and IL-2 plus TIL, respectively).
With 750-cGy WBX, a small, albeit statistically significant, survival advantage
was observed due tothe direct effects ofradiationtherapy (MST = 21.0d with WBX
vs. 11.5 d without radiation in control mice;p<0.0001). No survivalbenefitwas seen
with the addition of IL-2 (MST = 21.0 d), however, in mice given both TIL and
IL-2 after 750-cGyWBX, asubstantialprolongation ofsurvialwas noted whencom-
pared with mice receivingWBX alone or WBX with IL-2 (MST of>120 d and 75%
FIGURE 1 . Comparison of
LTX with WBX. The data
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long-term survival compared with an MST of 21.0 d and 0% long-term survival
with bothWBX alone and WBX followed by IL-2 therapy;p <0.0001). These findings
are consistent with our earlier publication (4).
If750-cGy LTX was deliveredto the liveralone, prolongation ofsurvival wasagain
noted in control mice due to a direct antitumor effect (MST = 20.0 d vs. 11.5 d
in mice treated with HBSS alone; p <0.0001), and in mice treated with the combi-
nation ofLTX, IL-2,and TIL (MST = 65.0 d and 41.7% long-term survival vs.
20.0 d and 0% long-term survival with LTX alone; p <0.0001). These findings are
similar tothosenoted above with WBX, although TIL therapywas slightly less suc-
cessfulwith LTX, possibly reflecting tumor that was missed bythe LTX port. How-
ever, unlike WBX, the addition ofIL-2 to LTX produced a substantial increase in
the MST (MST = 38.5 vs. 20.0d in micetreated with LTX alone;p<0.0001). This
antitumor activity mediated bythe combinationofLTXand IL-2 represents acom-
ponent ofhost immunity that was recruited by IL-2 administration after LTX but
not after WBX.
Finally, when WBX was used while shielding the liver (WBX/S), no therapeutic
advantagewas noted in anyofthetreatment groups, evenwhen compared withmice
receiving no radiation therapy (MST = 10.0, 11.0, and 11.0 vs. 11.5 d for WBX/S
+ HBSS, WBX/S + IL-2, and WBX/S + IL-2 + TIL vs. HBSS alone, respec-
tively). Thus, irradiation of the tumor-bearing organ rather than total body lym-
phoid suppression appeared necessary for the therapeutic effect ofTIL. Further-
more, when total body immunosuppression was avoided (as with LTX), a potent
antitumor effect mediated by IL-2 administration alone became evident.
Dose-dependent EffectsofLTX.
￿
A dose titration ofLTX was performed to ascertain
thelevel ofradiationforthe augmentation ofTIL-mediated antitumor effects. Mice
bearing 6-d MC-38 hepatic metastases received 0-, 250-, 500-, or 1,000-cGy LTX.
1 d later, mice from each radiation group were given immunotherapy with HBSS,
IL-2 (25,000 U i.p.) thrice daily for 5 d, or a single dose of 1.3 x 10' TIL intrave-
nously on day 7 followed by IL-2 (25,000 U i.p.) thrice daily for 5 d. Upon comple-
tion ofthe immunotherapy regimen, the mice were followed for survival. All dead
animals were autopsied for the presence of tumor. The results, illustrated in Fig.
2, demonstrated that doses ofat least 500 cGy are necessary to impact on survival.
Treatment with LTX in the absence ofimmunotherapy (HBSS-treated groups) ex-
hibited a dose-dependent prolongation in survival (MST = 12, 13.5, 18, and 25 d
in the 0-, 250-, 500-, and 1,000-cGy groups, respectively). With 500 and 1,000 cGy
(as with 750 cGy in the previous experiments), a survival benefit was seen in mice
given IL-2 alone when compared with mice treated with LTX alone (p <0.02). Fur-
thermore, the addition ofTIL to the immunotherapy regimen enhanced the sur-
vival benefit over that produced by IL-2 alone (p <0.05). The effects in both IL-2
alone and IL-2 combined with TIL were much more pronounced at the highest
dose of LTX.
Lymphoid Effects ofLTX Therapy.
￿
To further address the role of immunosuppres-
sion in the treatment of established MC-38 macrometastases with TIL and IL-2,
groups ofthreenormal mice were treated with the same radiation protocols as used
in the previous experiments: (a)no radiation; (b) 750-cGyWBX with bonemarrow
reconstitution; (c) 750-cGy LTX; and (d) 750-cGy WBX excluding the liver. After
1, 3, and 5 d, blood was collected for determination ofperipheral white blood cell254
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DAYS AFTER TUMOR INJECTION
(WBC) counts. Subsequently, the mice were killed, and their spleens, femurs, and
tibias were individually harvested to ascertain bone marrow and splenic cellularity.
The results from two repeated experimentswere similar. Data from one representa-
tive experiment shows that all three radiation regimens significantly reduced the
peripheral WBC on day 1 (312 ± 30, 440 t 17, and 468 t 23 .5 in W$X, LTX,
and WBX/S vs. 2,404 t 207 in the no radiation group, respectively; p <0.05). In
the two groups that included liver radiation (WBX and LTX), the counts remained
significantly depressed on days 3 and 5 (p <0.05), although by day 5 the counts in
all groups had begun to recover.
In a similar manner, splenic cellularity was decreased on day 1 in all radiation
groups, compared with HBSS-injected controls (1.2 t 0.6, 5.8 t 2.6, 11.3 t 1.8,
and 52 .0 t 11.0 x 106 cells/spleen in WBX, LTX, WBX/S, and normal control
groups, respectively; p <0.05). By day 5, however, all groups had begun to recover.
Bone marrow cellularity was also significantly depressed afterWBX with or without
liver shielding (0.4 t 0.12, 0.7 ± 0.07, and 9.0 ± 1.0 x 106 cells/femur in WBX,
WBX/S, and no radiation control groups, respectively; p <0.05), and the counts in
groups receiving radiation to the long bones and pelvis (WBX and WBX/S) con-
tinued to be substantially depressed on days 3 and 5 (th <0.05). While the femur
cellularity of mice treated with LTX was found to be intermediate but statistically
decreased on day 1 (5.0 t 0.4 vs. 9.0 t 1.0 x 106 cells/femur in LTX vs. no ir-
radiation; p < 0.05), it was not different from control mice on days 3 or 5. Thus,CAMERON ET AL.
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the immunosuppressionobserved inthese experiments correlated well withthe organs
irradiated. Thatis, thebone marrowwas suppressed most in animals receivingradi-
ation to the marrow-containing long bones (WBX and WBX/S), and the splenic
cellularitywas most suppressed when the liverand spleen were included in theradi-
ation field (WBX and LTX).
TheEffects ofPartial LTXon Immunotherapy with IL-2 and TIL.
￿
To detect the pos-
sibleexistence oftumor-associated Ts cellsthatmaybeeliminated with WBX, LTX,
and aspreviouslyreported, withCP, mice bearing6-d MC-38hepaticmacrometastases
were treated with: (a) no radiation; (b) WBXwith bonemarrow reconstitution; and
(c) radiation to the right side of the liver, shielding the left side (LTXli2). The fol-
lowing day, immunotherapy was begun in each radiation group with HBSS (0.5 ml
i.p.) thrice daily for 5 d, IL-2 (50,000 U i.p.) thrice daily for 5 d, or 1.2 x 10' TIL
given intravenously on day 7 followed by IL-2 (50,000 U i.p.) thrice daily for 5 d.
On day 17, themicewere killed andthelivers harvested. The numberoflivermetastases
on the left and right sides ofthe liver were individually counted in ablinded, coded
fashion. The experimentwasrepeated five times, and the results from one represen-
tative experiment are listed in Table I. As with the previous survival experiments,
no substantial effect wasnotedon either side ofthe liverinthe absence ofany radia-
tion therapy (mean numberofmetastases inthe HBSS, IL-2, and IL-2 + TIL groups
were [left/right] 500/500, 500/500, and 432 t 16.7/451 t 12.1, respectively). With
WBX, a marked reduction in the number ofmetastases on both sides was observed
in animals receiving IL-2 + TIL (14.4 t 20.8/3.2 t 3.4 metastases vs. 500/500
TABLE I
Treatment of Hepatic Macrometastases with Limited LTX and TIL
" No radiation, 750-cGy WBX, or 750-cGy LTX was given on day 6 after tumor injection. On day 7, im-
munotherapy was begun with HBSS alone, IL-2 (50,000 U i.p.) thrice daily for 5 d, or a single dose of
107 TIL on day 7 followed by IL-2 (50,000 U i.p.) thrice daily for 5 d.
: The liver was divided into left and right sides based on lobes. The right side consisted of one large lobe
and two intermediate-sized lobes, while the left side consisted of one large lobe, one intermediate-sized
lobe, and one small lobe. The total volumes of each side were approximately equal.
S All radiation was delivered using an X-ray machine (Philips Electronic Instruments, Inc.) operating at
235 kV and 15 mamps and delivering 63 cGy/min.
II Metastases were identified as white nodules on a dark, India ink-stained background. The number of
metastases was counted to a maximum of 500, and if the metastases were too numerous to count, a value
of 500 was assigned. All experiments were counted in a blinded, coded fashion.
p < 0.02 compared with radiation alone and radiation combined with IL-2.
" Mice treated with LTX received radiation only to the right side of the liver with shielding of the left side.
It p < 0.05 compared with radiation alone and radiation combined with IL-2.
SS p < 0 .01 compared with radiation alone and radiation combined with IL-2.
Treatment' Left side: Right side:
XRTS IL-2 TIL Metastasesll Mean t SEM Metastasesll Mean t SEM
500,500,500 500 500,500,500 500
500,500,500,500,500,500 500 500,500,500,500;500,500 500
- + + 500,500,500,500,500,92 432 f 16 .7 500,500,500,500,500,204 451 t 12 .1
WBX - - 500,500,500,500 500 500,500,500,500 500
WBX + - 500,500,500 500 500,500,500 500
WBX + + 0,3,8,10,51 14.4 t 20.81 8,5,3,0,0 3.2 t 3 . 411
LTX" - - 500,500,500,500,500 500 500,500,500,500,136 427 16.3
LTX + - 500,500,500,500,500,500 500 500,500,500,500,500,207 451 t 21.8
LTX + + 500,500,152,101,77,15 224 t 21 .8:: 500,2,0,0,0,0 83.7 t 20ASS256
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in both theWBX + HBSS andWBX + IL-2 groups ; p <0.02) . Finally, metastases
on either side of the liver were not significantly reduced in animals receiving LTXli2
and either HBSS or IL-2 (500/427 t 16.3 and 500/451 t 21.8, respectively) . How-
ever, when LTX1i2 was combined with IL-2 and TIL, a highly significant reduc-
tion in the number of right-sided metastases was seen (83 .7 t 20.4 ; p <0 .01) . In
addition, the number of metastases on the left side of the livers was also moderately
reduced (224 t 218 vs. 500 t 0 in both the HBSS- and IL-2-treated groups ; p
<0.02) . A photograph of the gross pathologic appearance of a liver treated with
LTXv2, IL-2, and TIL is provided in Fig . 3 . Therefore, despite the presence of
unirradiated tumor cells and theoretically suppressor cells in the same organ, no
suppression in the antitumor effects ofIL-2 andTILwas apparent . The slight reduction
observed in the left-sided metastases suggests that the antitumor effects of IL-2 and
TIL may extend to the unirradiated side as well, although partial irradiation of the
FIGURE 3.
￿
Partial LTX . Mice bearing 6-d MC-38 hepatic metastases received no radiation
therapy, 750-cGyWBX, or 750-cGy X-ray irradiation to the right side of the liver with the left
side shielded. 1 d later (day 7), immunotherapy wasbegunwith HBSS, IL-2 (2,000U i.p.) thrice
daily for 5 d, or one intravenous dose of 1.3 x 107 TIL followed by IL-2 (2,000U i.p.) thrice
daily for 5 d .On day 17 after tumor injection, the mice were killed and thenumber ofmetastases
on each side of the liver was counted. The data shown are representative of five experiments .CAMERON ET AL.
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left side of the liver could also explain this finding. These results, however, are not
consistent with the existence of suppressor cells, since a substantial antitumor effect
was seen in the right side of the liver in the presence of extensive tumor in the left
side of the liver.
TheAntitumorEffects ofIL-2 and TIL in BMice.
￿
To assess the postulated existence
ofsuppressor cellsin adifferentmodel, 8-wk-old C57BL/6 mice underwent thymec-
tomy followed 2 wk later by lethal y irradiation and bone marrow reconstitution
usingT -depletedbone marrow. Before using B mice in immunotherapy experiments,
splenocytes from theseanimalswere tested for allogeneic responsiveness as measured
by an anti-DBA mixed lymphocyte reaction (MLR). Normal C57BL/6 splenocytes
were compared with those obtained from B mice. In response to DBA allogeneic
antigens, normal splenocytes proliferated by day 2, and on day 4, the response had
increased, as measured by [3H]thymidine incorporation (net cpm = 68,959, com-
pared with normal splenocytes stimulated with syngeneic cells). The B mouse spleno-
cytesdidnot respondat either time point(net cpm = -4,325 compared with B sple-
nocytes stimulated with syngeneic cells). In other experiments, mice were injected
intravenously with tumor cell suspensions to induce pulmonary metastases. After
14 d, splenocytes from these animals were also assayed for T cell activity in an anti-
DBA MLR. The results from these experiments showed that these mice continued
to lack allogeneic responsiveness at the time immunotherapy was instituted (data
not shown). Since splenectomy was performed after the induction of multiple liver
metastases, these animals were not tested after the injection of tumor.
After demonstrating that B mice produced in this manner were devoid of T cell
responsiveness both before and after tumor injection, 6-d multiple hepatic macro-
metastases were generated in both normal and B mice. Some mice from each group
were then treatedwith CP (100 mg/kg), followed by HESS, IL-2, or IL-2 combined
with TIL. These data are depicted in Fig. 4. CP was chosen since the B mice had
alreadyreceived >1,000 cGY andgenerally do not tolerate more radiation, and since
CP and WBX both augment TIL antitumor activity in a similar manner. As in
the radiation experiments, no effect was seen in either normal or B mice in the ab-
sence of CP. In normal mice receiving HBSS, IL-2, and IL-2 in combination with
TIL, the MSTs were 18.0, 14.0, and 20.0 d, respectively, while in B mice, the same
treatments resulted in MSTs of 25.0, 22.0, and 18.5 d. If CP was administered in
normal mice, a significant survival advantage was noted (MST = 34.5 d with CP
and HBSS vs. 18.0 d with HBSS alone) . Similarly, CP administration in B mice
prolongedthe survival of HBSS-treated mice, albeit to alesser degree (MST = 30 .5
vs. 25.0 din HBSS controlmice). When IL-2 was addedto both normal and B mice,
an additional prolongation in survival was noted (45.5 d in normal and 48.0 d in
B mice). This is similar to previously reported synergy between CP and IL-2 (13).
When TIL were then added to the immunotherapyregimen, all normal and B mice
survived tumorfree for>120 d (p <0.0008 vs. HBSS- and IL-2-treated mice). Thus,
in both normal mice and mice depleted of T cells, the therapeutic efficacy of TIL
depended on the use of CP. These data, along with the results from the LTXli2 ex-
periments, suggestthat the mechanism of radiation augmentation ofTIL antitumor
activity is notdependent on the elimination ofmature Tlymphocyte suppressor cells.
TheDirect AntitumorEffect ofCPandRadiation Therapy.
￿
To investigate alternatemech-
anisms of interaction between CP/WBX and TIL immunotherapy, we measured258
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Immunotherapy of
B mice. Both normal and B
mice bearing 10-d MC-38 he-
patic metastases were given ei-
ther no injectionor asingle in-
travenous injection of 2 mg of
cyclophosphamide (100 mg/kg).
24 h later, groups of six mice
each were then treated with
HBSS, IL-2 (7,500 Ui.p.) thrice
daily for 5 d, or a single dose
of 5 x 106 TIL intravenously
combined with IL-2 (7,500 U
i.p.) thrice daily for 5 d Aft ter
completion of immunotherapy,
themice were followed for sur-
vival. Upondeath, allmicewere
autopsied to confirm the pres-
ence of tumor.
DAYS AFTER TUMOR INJECTION
the direct antitumor activity of both CP and WBX, as well as that of adriaxnycin
(ADR). Mice were injected with MC-38 adenocarcinoma intrasplenically to induce
multiple hepaticmetastases in an identical manner to that previously described. After
10 d, groups of three mice were given one of five therapeutic treatments: HBSS,
500-rad WBX, 1,000-radWBX, CP (200 mg/kg), andADR (10 mg/kg). After 24 h,
the mice were killed, andthelivers were sterilely harvested. Subsequently, thelivers
were digested with triple enzyme solution, and the resulting tumor cell/hepatocyte
suspension from each treatment group was washed three times and placed into a
clonogenic assay. Five 1:10 serial dilutions of each treated cell type (106-102) were
plated into triplicate wells of six-well plates, as described in Materials and Methods.
After 14 d, the colonies were stained and counted. The resultsof two similar experi-
ments are shown in Table II. With no treatment (HBSS), N51% and N37% of the
cells plated in Exp. 1 and 2, respectively, grew into colonies with the histologic ap-
pearance of MC-38 adenocarcinoma, indicating that one-third to one-half of the
liver had been replaced by tumor. Rarely, small fibroblast colonies were noted, how-
ever, these were not counted. WBX reduced the number of colonies formed per 106
cells plated in adose-dependent manner. Irradiation with 500 cGy lowered theability
of the tumor cells to form colonies by 92.8 and 55.2 times and 1,000 cGy by 1,159
and 507 times. CP had a similar potent antitumor effect, lowering the clonogenic
potential by 662 and 1,276 times but ADR, which does not synergize with IL-2,
failed to decrease the clonogenic potential >68.9 times in either experiment. This
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TABLE 11
The Direct Antitumor Effects of Radiation and Chemotherapy
' Mice bearing multiple 10-d MC-38 hepatic (Exp. 1) or pulmonary (Exp. 2) metastases were
treated with HBSS intraperitoneally, 500-cGyWBX, 1,000-cGyWBX, CP (200 mg/kg i.v.),
or ADR (10 mg/kg i.v.), and after 24 h, the livers were harvested, digested, and the result-
ing cells plated into clonogenic assays.
t The mean number of colonies formed in triplicate wells is expressed per 106 cells plated.
s The reduction in the mean no. CFU/106 cells is compared with the HBSS-treated controls.
II All groups are statistically significnatly different from each other by student's t test (p < 0.05).
suggests that agents that are known to synergize with IL-2 and TIL are those that
have direct antitumor effects against the MC-38 adenocarcinoma.
Discussion
The adoptive transfer ofTIL in combination with the administration ofIL-2 has
been shown to mediate the regression of established tumor in mice as well as man
(5-7). In murine tumor models, successful immunotherapy ofestablished 6- and
14-dmetastatic diseasewith TILandIL-2 requires theadministration ofCP orWBX.
This requirement has been attributed to one ofthe following: (a) the need to elimi-
nate endogenous systemic suppressor cells that, in at least one model, have been
shown to depress active T cell-mediated antitumor activity (8, 9); (b) a direct an-
titumor action mediated through either a direct cytotoxic mechanism or through
increased tumor susceptibilityto TIL cytolysis; (c) the creation of"lymphoid" space
either in the tumor or lymph organs that TIL require in order to exert their an-
titumor activity; or (d) to facilitate increased cell trafficking to the tumor.
We have shown that LTX, in a MC-38 murine hepatic metastatic model, aug-
ments the antitumor effects ofTIL in a manner similar to WBX and CP. Further-
more, LTX significantly enhances theantitumor activity ofIL-2 inamanner similar
to that previously shown for CP administration (13). WBX, however, does not in-
crease the effectiveness of immunotherapy with IL-2, but rather, in the absence of
adoptively transferred cells, it abrogates any activity of systemic IL-2 administra-
tion. In the experiments depicted in Figs. 1 and 2, no antitumor effects were ob-
served with the adoptive transfer ofTIL unless the tumor itself was irradiated with
either LTX or WBX. Even if WBX excluding the liver was given, which produces
immunosuppressionnotunlike WBX andLTX, noantitumoreffects were seen. These
findings indicate that the primary action of WBX and LTX occurs at the site of
the tumor itself and not on the extratumoral immune cells, including any existing
systemic suppressor cells (all mice have undergone splenectomy, and therefore, the
majority of immune cells are found outside of the radiation field). These experi-
Treatment'
Mean no.
CFU/106 cellst
Fold
reductions
Mean no.
CFU/106 cells:
Fold
reductions
HBSS 510,000 t 51,00011 - 370,000 t 107,000" -
500 cGy 5,500 t 450 92.8 6,700 t 250 55.2
1,000 cGy 440 t 54 1,159 730 t 60 507
CP 770 t 90 662 290 t 30 1,276
ADR 7,400 t 350 68.9 21,000 t 3,100 17.6260
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ments, however, do not eliminate the possible existence of intratumoral Ts cells or
any ofthe other explanations for the synergistic interaction between CP/WBX and
TIL discussed above.
To furtherclarifythe role ofTs cells and, inparticular, to evaluate the roleofintra-
hepatic suppressor cells in the immunotherapy ofMC-38hepatic macrometastases,
the right halfofthe liver was irradiated while shielding the left lobes to determine
theantitumoreffects ofTIL in the presenceofunirradiated tumorand, presumably,
Ts cells in the same organ. The results shown in Table I clearly indicate that the
TILremain effectivein reducing thenumberofhepatic metastases on the irradiated
right side. No suppression oftheir effectiveness was noted, and, as depicted in Fig.
3, adistinct linedemarcatingtheirradiated and unirradiated liver was evident. These
findings, while not constituting absolute evidence, are highly suggestive that irradi-
ation does not eliminate suppressor cells, since the efficacy ofTIL on the right side
ofthe liverwas not affected bythe possible presence ofsuppressor cells on the oppo-
site side.
To further test the possible role of Ts cells, we investigated the effect ofTIL in
B mice bearing macrometastatic tumor. These mice were shown to be devoid ofT
cell responsiveness as measured by an anti-DBA MLR. IfTs cells were responsible
for the inhibition ofTIL, immunotherapy with TIL in B mice should not require
CP or radiation therapy; as shown in Fig. 4, this is not the case. Even in B mice,
CP was required for thetherapeutic efficacy ofadoptively transferred TIL. In addi-
tion, CP also incremented the effect ofIL-2 alone in a manner similar to that seen
in normal animals, possibly through the in vivo induction of LAK cells. Thus, in
mice lackingdetectablefunctional mature T cells, CP was still required for success-
ful immunotherapy with TIL and IL-2, indicating that CP (and probably WBX
and LTX as well) did not eliminate intratumoral Ts cells as its primarymechanism
ofaction. Creation oflymphoid space also is not consistent with these findings since
adult T lymphocytes are not present in B mice.
Since CP, WBX, and LTX did not appear to synergize with TIL and IL-2 by
eliminating Ts cells, we investigated the direct antitumor activity against MC-38
as a possible mechanism ofaction. As shown by the clonogenic assay in Table II,
WBX at either 500 or 1,000 cGy, as well as CP (100 mg/kg), had potent direct an-
titumor activity. ADR, however, which does not synergize with IL-2 in the treat-
ment ofweakly immunogenic murine sarcomas, as shown in previous studies (13),
only produces a mild reduction in clonogenic potential at similar published ther-
apeutic doses (10 mg/kg). These data indicate that agents that possess strong an-
titumoractivity againstthe treated tumorare most likely to augment the antitumor
effects of TIL. Furthermore, in several experiments designed to evaluate the lysa-
bility of 10-d MC-38 liver and lung metastases after treatment with radiation, CP,
or WBX, we were unable to demonstrate consistent changes in tumor lysability by
TIL (data not shown). Therefore, the most likely action of radiation and CP re-
mains a direct antitumor activity, although alterations in cell trafficking due to ei-
therincreasedlocal inflammation orsome otherunknownfactor cannot be excluded.
The need fordirect antitumor agents in addition to therapy withTIL and IL-2 may
be due to: (a) a need to decrease tumor bulk so that TIL are required to lyse fewer
cells before they themselves die; (b) a need to slow the growth of the tumor so that
the rate oftumor cell lysis by TIL exceeds that oftumor growth; or (c) a need toCAMERON ET AL.
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inhibitthetumorproduction ofsuppressive factors, such as TGF0, that havebeen
shown to inhibit the function ofimmune cells (14-16). Experiments to differentiate
these possibilities represent important areas of future research.
The most significant clinically useful dataderived from these experiments, how-
ever, istheinteractionbetween LTXandTIL. To date, LTXhasnotbeen administered
before immunotherapy, since WBX had been shown in many instances to inhibit
the immune system. However, the present studies show that LTX can be success-
fully combined with both IL-2 and TIL in the immunotherapy ofa murine adeno-
carcinoma. The usefulness of this combination in man remains to be determined,
and we have begun clinical trials designed to answer this question.
Summary
The adoptive transfer oftumor-infiltrating lymphocytes (TIL)with the concomi-
tant administration ofIL-2 hasbeen shownto mediatethe regression ofestablished
6- and 14-d murine hepatic and pulmonary metastases. Forsuccessful immunotherapy
with TIL, however, pretreatment witheither cyclophosphamide (CP)orwhole body
irradiation(WBX)was required. TheexactmechanismofCP and WBXaugmenta-
tion ofTIL antitumor activity remains unknown, but the elimination of Ts cells
has been frequently invoked as an explanation. To address this possibility and to
determineiflocal tumorirradiation (LTX) couldsynergizewith TILas wellasWBX,
we investigated the effect of LTX on the therapeutic efficacy ofTIL and IL-2 in
the treatmentofmultiple 7-dmurine hepatic metastases. Experiments studyingthe
treatment of a weakly immunogenic murine adenocarcinoma, MC-38, showed
prolonged survival of mice treated with the combination ofIL-2, TIL, and either
LTXorWBX, compared with treatmentwith radiation alone orradiation plus IL-2
controls (p <0.0001). In addition, therapy with LTX and IL-2 prolonged survival,
compared with LTX administration alone, whereas therapy with WBX combined
with IL-2 did not alter survival. This augmentation ofTIL-mediated antitumor ac-
tivity was dependent on the dose of radiation used. To assess the possibility that
tumor-associated Tscellsinhibit the function ofadoptivelytransferredTILin animals
with 7-d metastatic tumor and are eliminated by WBX and LTX, we repeated the
above experiments leaving some tumor unirradiated. Mice underwent either LTX
or limited LTX, which included only the right side of the liver (LTXii2). The
number of right- and left-sided metastases were then individually counted. These
studies showed thatthe reduction in the numberofright-sided metastases was iden-
tical between the two groups and that the presenceofleft-sided tumor in the LTXli2
group did not suppress the observed antitumor activity ofTIL against irradiated
tumor. Additional evidence against the elimination ofsuppressor cells as an impor-
tant mechanism in radiation-induced augmentation ofTIL antitumor activity was
providedby experimentsstudyingthe effectiveness ofTIL inthymectomized, lethally
irradiated, and reconstituted B mice. Unless CP was administered before the adop-
tive transfer ofTIL, therapy with IL-2 and TIL in these B mice was ineffective in
the absence ofdemonstrable T lymphocytes. Finally, clonagenic assays performed
after treatment with CP, adriamycin, or WBX demonstrated that the degree of di-
rect antitumor activity exhibited by these agents correlated well with their known
ability to synergize with TIL and IL-2. Thus, these experiments not only provide
evidence of a synergistic interaction between LTX and TIL in general, but they262
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also provide indirect data contradicting a critical role for suppressor cells in the
radiation- and CP-mediated therapeutic augmentation of TIL and IL-2. In addi-
tion, the marked synergy between LTX and TIL provides a rational basis for clin-
ical trials designed to determine the extent to which LTX and TIL interact in the
treatment of human malignancies.
Receivedfor publication 26 June 1989 and in revised form 6 October 1989.
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